Trial · NCT07879989
Respiratory Progression in Adults With Duchenne Muscular Dystrophy.
NCT07879989, Recruiting, Istituto Giannina Gaslini
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Respiratory Progression in Adults With Duchenne Muscular Dystrophy. Trials, record NCT07879989. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879989
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Respiratory Progression in Adults With Duchenne Muscular Dystrophy.
- NCT number
- NCT07879989
- Status
- Recruiting
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Istituto Giannina Gaslini
- Conditions
- Duchenne Muscular Dystrophy (DMD), Respiratory Function Decline, Restrictive Lung Disease, Respiratory Failure, Sleep-disordered Breathing
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Characterization of Respiratory Progression in Adults with Duchenne Muscular Dystrophy | 36 months; retrospective data collected from the earliest available assessment and prospective respiratory and motor assessments performed every 6 months. | Longitudinal characterization of respiratory disease progression through the collection of clinical, respiratory, motor, and genetic data, including changes in forced vital capacity (FVC), FVC percentage predicted, and sniff nasal inspiratory pressure (SNIP). |
| Secondary | Association of Motor, Respiratory, and Genetic Factors with Respiratory Failure | 36 months; respiratory and motor assessments every 6 months. | Assessment of the association between motor function, respiratory parameters, and DMD gene mutations and the risk of respiratory failure, defined by the need for non-invasive ventilation (NIV) and/or nocturnal hypoventilation, or severe restrictive lung disease defined as FVC percentage predicted below 50%. |
| Secondary | Validation of Diaphragm Ultrasound in Adults with Duchenne Muscular Dystrophy | During the 36-month study period; ultrasound assessments in the designated subgroup and healthy controls. | Validation of diaphragm ultrasound by comparing diaphragm thickening fraction, thickness, and excursion in patients with DMD and healthy controls, and assessing their association with respiratory function, motor function, and DMD gene mutations. |
| Secondary | Development of a Composite Clinical and Genetic Severity Score | Within the 36-month study period, using collected clinical, motor, respiratory, and genetic data. | Development of a composite score classifying patients according to mild, moderate, or severe disease and their risk of developing respiratory failure or severe restrictive lung disease (FVC percentage predicted below 50%), based on clinical and genetic variables. |
| Secondary | Identification of Genetic and Serum Biomarkers of Respiratory Disease Progression | 36 months; genetic samples collected once and serum inflammatory biomarkers collected annually. | Evaluation of the prognostic role of genetic modifiers and serum inflammatory biomarkers, including IL-6, IL-10, IL-1β, IL-12, TNF-α, TGF-β, VCAM-1, and ICAM-1, and their association with annual changes in FVC percentage predicted and the risk of respiratory failure or severe restrictive lung disease. |
| Secondary | Development of a Predictive Algorithm for Respiratory Disease Progression | By the end of the 36-month study period, using retrospective and prospectively collected data. | Development of predictive models to estimate individual risk and progression rate for respiratory failure requiring NIV, nocturnal hypoventilation, and severe restrictive lung disease (FVC percentage predicted below 50%), based on clinical, motor, respiratory, and genetic predictors. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879989
GET https://conductscience.org/api/trials/v1/NCT07879989/registered